Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
445 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Non-Hodgkin Lymphoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2014', provides an overview of the Non-Hodgkin Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Non-Hodgkin Lymphoma Overview 12 Therapeutics Development 13 Pipeline Products for Non-Hodgkin Lymphoma - Overview 13 Pipeline Products for Non-Hodgkin Lymphoma - Comparative Analysis 14 Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 15 Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 22 Non-Hodgkin Lymphoma - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Unknown Stage Products 27 Non-Hodgkin Lymphoma - Products under Development by Companies 28 Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 35 Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 36 AbbVie Inc. 36 Accentia Biopharmaceuticals, Inc. 37 Acetylon Pharmaceuticals, Inc. 38 Actinium Pharmaceuticals, Inc. 39 AlphaMab Co., Ltd 40 Amgen Inc. 41 Astellas Pharma Inc. 42 Astex Pharmaceuticals, Inc. 43 Avipep Pty Ltd 44 Bayer AG 45 BioInvent International AB 46 Biothera, Inc. 47 Bristol-Myers Squibb Company 48 Calithera Biosciences, Inc. 49 Celgene Corporation 50 Celltrion, Inc. 51 CIMAB S.A. 52 Conkwest, Inc. 53 Constellation Pharmaceuticals, Inc. 54 Cornerstone Pharmaceuticals, Inc. 55 CTI BioPharma Corp. 56 Curis, Inc. 57 Dicerna Pharmaceuticals, Inc. 58 Dynavax Technologies Corporation 59 Eisai Co., Ltd. 60 Eli Lilly and Company 61 Epirus Biopharmaceuticals, Inc. 62 EpiZyme, Inc. 63 F. Hoffmann-La Roche Ltd. 64 Fountain Biopharma Inc. 65 Gamida Cell Ltd. 66 Genentech, Inc. 67 Gilead Sciences, Inc. 68 GlaxoSmithKline plc 69 Grupo Ferrer Internacional, S.A. 70 Hetero Drugs Limited 71 Immunomedics, Inc. 72 Inbiopro Solutions Pvt. Ltd. 73 Innovent Biologics, Inc. 74 Johnson & Johnson 75 Kainos Medicine, Inc. 76 Karyopharm Therapeutics, Inc. 77 Merck & Co., Inc. 78 Millennium Pharmaceuticals, Inc. 79 Mirna Therapeutics, Inc. 80 Mission Therapeutics Ltd 81 MorphoSys AG 82 Novartis AG 83 NovImmune SA 84 NuCana BioMed Limited 85 Oncobiologics, Inc. 86 Otsuka Holdings Co., Ltd. 87 Oxford BioTherapeutics Ltd 88 Panacea Biotec Limited 89 Pfizer Inc. 90 Pharmacyclics, Inc. 91 Polaris Group 92 Portola Pharmaceuticals, Inc. 93 ProNAi Therapeutics, Inc. 94 Richter Gedeon Nyrt. 95 Sanofi 96 Seattle Genetics, Inc. 97 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 98 Shanghai Henlius Biotech Co., Ltd. 99 Sigma-Tau S.p.A. 100 Spectrum Pharmaceuticals, Inc. 101 Supratek Pharma Inc. 102 Taiwan Liposome Company, Ltd. 103 Tekmira Pharmaceuticals Corp. 104 TG Therapeutics, Inc. 105 The International Biotechnology Center (IBC) �Generium� 106 Tolero Pharmaceuticals, Inc. 107 Transgene Biotek Limited 108 Vivia Biotech, S.L. 109 Xenetic Biosciences plc 110 Zymeworks Inc. 111 Non-Hodgkin Lymphoma - Therapeutics Assessment 112 Assessment by Monotherapy Products 112 Assessment by Combination Products 113 Assessment by Target 114 Assessment by Mechanism of Action 120 Assessment by Route of Administration 126 Assessment by Molecule Type 128 Drug Profiles 130 (19)-3s - Drug Profile 130 abexinostat hydrochloride - Drug Profile 131 AG-221 - Drug Profile 133 AGS-67E - Drug Profile 135 alisertib - Drug Profile 136 alvocidib hydrochloride - Drug Profile 140 AMG-319 - Drug Profile 141 Antibody Conjugate for Non-Hodgkin lymphoma - Drug Profile 142 AT-7519 - Drug Profile 143 AVP-5 - Drug Profile 146 bendamustine hydrochloride - Drug Profile 147 bendamustine hydrochloride - Drug Profile 149 BI-1206 - Drug Profile 150 blinatumomab - Drug Profile 151 BMS-986016 - Drug Profile 154 brentuximab vedotin - Drug Profile 155 CB-839 - Drug Profile 160 CC-115 - Drug Profile 161 CC-122 - Drug Profile 162 CC-223 - Drug Profile 164 Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 165 Cell Therapy 3 for Oncology - Drug Profile 166 Cell Therapy for Hematological Malignancies - Drug Profile 167 Cell Therapy for Oncology - Drug Profile 168 Cell Therapy for Oncology - Drug Profile 169 Cell Therapy for Oncology and Infectious Diseases - Drug Profile 170 Cell Therapy to Inhibit CD19 for Non-Hodgkin Lymphoma - Drug Profile 171 Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 172 Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas - Drug Profile 173 cerdulatinib - Drug Profile 174 copanlisib - Drug Profile 175 CPI-0610 - Drug Profile 178 CPI-613 - Drug Profile 179 CST-103 - Drug Profile 181 CUDC-907 - Drug Profile 182 daratumumab - Drug Profile 184 dasatinib - Drug Profile 187 dasiprotimut-T - Drug Profile 190 DCRM-1711 - Drug Profile 192 Dendritic Cell Therapy for Oncology - Drug Profile 193 Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 194 DMS-612 - Drug Profile 195 E-7438 - Drug Profile 196 EPZ-5687 - Drug Profile 198 FB-811 - Drug Profile 200 FIB-114 - Drug Profile 201 GNR-022 - Drug Profile 202 GS-9973 - Drug Profile 203 GSK-2816126 - Drug Profile 204 I-Tenatumomab - Drug Profile 205 IBPM-001RX - Drug Profile 206 IGN-002 - Drug Profile 207 IMMU-110 - Drug Profile 208 IMMU-114 - Drug Profile 210 Imprime PGG - Drug Profile 211 Iomab-B - Drug Profile 215 JCAR-014 - Drug Profile 217 KM-301 - Drug Profile 218 KML-001 - Drug Profile 219 KN-001 - Drug Profile 221 lenalidomide - Drug Profile 222 LMP-400 - Drug Profile 225 LMP-776 - Drug Profile 227 LY-2780301 - Drug Profile 228 MK-2206 - Drug Profile 229 MN-2 - Drug Profile 232 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 233 Monoclonal Antibody 2 Conjugates for Cancer - Drug Profile 234 Monoclonal Antibody to Inhibit CD20 for Non-Hodgkin Lymphoma and Rheumatoid Arthritis - Drug Profile 235 MOR-208 - Drug Profile 236 MRX-34 - Drug Profile 238 NI-1701 - Drug Profile 240 NiCord - Drug Profile 241 NSC-678515 - Drug Profile 242 NUC-1031 - Drug Profile 243 obinutuzumab - Drug Profile 245 Oncohist - Drug Profile 247 OPB-51602 - Drug Profile 249 pegargiminase - Drug Profile 251 pembrolizumab - Drug Profile 254 PF-05082566 - Drug Profile 257 pictilisib - Drug Profile 258 pixantrone dimaleate - Drug Profile 260 PNT-2258 - Drug Profile 264 procarbazine hydrochloride - Drug Profile 266 PUH-71 - Drug Profile 267 ricolinostat - Drug Profile 269 rituximab biosimilar - Drug Profile 271 rituximab biosimilar - Drug Profile 273 rituximab biosimilar - Drug Profile 274 rituximab biosimilar - Drug Profile 275 rituximab biosimilar - Drug Profile 276 rituximab biosimilar - Drug Profile 277 rituximab biosimilar - Drug Profile 278 rituximab biosimilar - Drug Profile 279 rituximab biosimilar - Drug Profile 280 rituximab biosimilar - Drug Profile 281 rituximab biosimilar - Drug Profile 282 RP-5264 - Drug Profile 283 SAR-650984 - Drug Profile 284 SD-101 - Drug Profile 285 selinexor - Drug Profile 287 SGN-CD70A - Drug Profile 290 SH-7139 - Drug Profile 291 Small Molecule for Hematologic Malignancies - Drug Profile 293 Small Molecules to Inhibit GLUT4 for Oncology - Drug Profile 294 StemEx - Drug Profile 295 TBL-0306L - Drug Profile 296 TG-1101 + TGR-1202 - Drug Profile 297 tisagenlecleucel-T - Drug Profile 298 TKM-PLK1 - Drug Profile 300 veltuzumab - Drug Profile 302 venetoclax - Drug Profile 305 vincristine sulfate - Drug Profile 308 vincristine sulfate liposomal - Drug Profile 311 vinorelbine tartrate - Drug Profile 312 vinorelbine tartrate liposomal - Drug Profile 313 Vivia-009 - Drug Profile 315 X-396 - Drug Profile 316 ZW-34 - Drug Profile 317 Non-Hodgkin Lymphoma - Recent Pipeline Updates 318 Non-Hodgkin Lymphoma - Dormant Projects 423 Non-Hodgkin Lymphoma - Discontinued Products 426 Non-Hodgkin Lymphoma - Product Development Milestones 427 Featured News & Press Releases 427 Appendix 436 Methodology 436 Coverage 436 Secondary Research 436 Primary Research 436 Expert Panel Validation 436 Contact Us 437 Disclaimer 437
List of Tables Number of Products under Development for Non-Hodgkin Lymphoma, H2 2014 21 Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2014 22 Number of Products under Development by Companies, H2 2014 24 Number of Products under Development by Companies, H2 2014 (Contd..1) 25 Number of Products under Development by Companies, H2 2014 (Contd..2) 26 Number of Products under Development by Companies, H2 2014 (Contd..3) 27 Number of Products under Development by Companies, H2 2014 (Contd..4) 28 Number of Products under Development by Companies, H2 2014 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2014 30 Comparative Analysis by Late Stage Development, H2 2014 32 Comparative Analysis by Clinical Stage Development, H2 2014 33 Comparative Analysis by Early Stage Development, H2 2014 34 Comparative Analysis by Unknown Stage Development, H2 2014 35 Products under Development by Companies, H2 2014 36 Products under Development by Companies, H2 2014 (Contd..1) 37 Products under Development by Companies, H2 2014 (Contd..2) 38 Products under Development by Companies, H2 2014 (Contd..3) 39 Products under Development by Companies, H2 2014 (Contd..4) 40 Products under Development by Companies, H2 2014 (Contd..5) 41 Products under Development by Companies, H2 2014 (Contd..6) 42 Products under Investigation by Universities/Institutes, H2 2014 43 Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H2 2014 44 Non-Hodgkin Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H2 2014 45 Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 46 Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 47 Non-Hodgkin Lymphoma - Pipeline by AlphaMab Co., Ltd, H2 2014 48 Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2014 49 Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2014 50 Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 51 Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H2 2014 52 Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2014 53 Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2014 54 Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H2 2014 55 Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 56 Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2014 57 Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2014 58 Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2014 59 Non-Hodgkin Lymphoma - Pipeline by CIMAB S.A., H2 2014 60 Non-Hodgkin Lymphoma - Pipeline by Conkwest, Inc., H2 2014 61 Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 62 Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 63 Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H2 2014 64 Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2014 65 Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2014 66 Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2014 67 Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2014 68 Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2014 69 Non-Hodgkin Lymphoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 70 Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2014 71 Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 72 Non-Hodgkin Lymphoma - Pipeline by Fountain Biopharma Inc., H2 2014 73 Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2014 74 Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2014 75 Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 76 Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline plc, H2 2014 77 Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 78 Non-Hodgkin Lymphoma - Pipeline by Hetero Drugs Limited, H2 2014 79 Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2014 80 Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 81 Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2014 82 Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2014 83 Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H2 2014 84 Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 85 Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 86 Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 87 Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2014 88 Non-Hodgkin Lymphoma - Pipeline by Mission Therapeutics Ltd, H2 2014 89 Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2014 90 Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2014 91 Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2014 92 Non-Hodgkin Lymphoma - Pipeline by NuCana BioMed Limited, H2 2014 93 Non-Hodgkin Lymphoma - Pipeline by Oncobiologics, Inc., H2 2014 94 Non-Hodgkin Lymphoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 95 Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 96 Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H2 2014 97 Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2014 98 Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 99 Non-Hodgkin Lymphoma - Pipeline by Polaris Group, H2 2014 100 Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 101 Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2014 102 Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H2 2014 103 Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2014 104 Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 105 Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2014 106 Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2014 107 Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2014 108 Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 109 Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H2 2014 110 Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 111 Non-Hodgkin Lymphoma - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 112 Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2014 113 Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) "Generium", H2 2014 114 Non-Hodgkin Lymphoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 115 Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H2 2014 116 Non-Hodgkin Lymphoma - Pipeline by Vivia Biotech, S.L., H2 2014 117 Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H2 2014 118 Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H2 2014 119 Assessment by Monotherapy Products, H2 2014 120 Assessment by Combination Products, H2 2014 121 Number of Products by Stage and Target, H2 2014 123 Number of Products by Stage and Mechanism of Action, H2 2014 129 Number of Products by Stage and Route of Administration, H2 2014 135 Number of Products by Stage and Molecule Type, H2 2014 137 Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 326 Non-Hodgkin Lymphoma - Dormant Projects, H2 2014 431 Non-Hodgkin Lymphoma - Discontinued Products, H2 2014 434
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.